Digestives & Intestinal Remedies - Lithuania

In Lithuania, the Digestives & Intestinal Remedies market market recorded a revenue of US$29.70m in 2024.
It is projected to experience an annual growth rate of 5.01% (CAGR 2024-2029).
Comparing globally, China generates the highest revenue in this market, amounting to US$4.41bn in 2024.
When considering the population, per person revenues reached US$11.03 in 2024.
Lithuania's Digestives & Intestinal Remedies market is witnessing a surge in demand for natural and herbal products.

Definition:
The Digestives and Intestinal Remedies market comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Digestives and Intestinal Remedies market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Natural and synthetic agents
Digestive medicines
Remedies against gastrointestinal complaints

Prescription medicines
Homeopathic remedies
Tea

The Digestives & Intestinal Remedies market in Lithuania has been experiencing steady growth in recent years, driven by changing customer preferences, emerging trends in the market, and local special circumstances. Customer preferences in the Digestives & Intestinal Remedies market in Lithuania have shifted towards natural and herbal remedies, as consumers become more health-conscious and seek products with fewer side effects. This trend is in line with the global market, where there is a growing demand for natural and organic products. Customers are also looking for products that are convenient and easy to use, such as chewable tablets or liquid formulations. Trends in the market include the rise of e-commerce and online sales channels. With the increasing availability of internet access and the convenience of online shopping, more consumers in Lithuania are turning to online platforms to purchase Digestives & Intestinal Remedies. This trend is not unique to Lithuania, as e-commerce has been growing worldwide. Additionally, there is a growing focus on personalized healthcare and self-care, with consumers seeking products that cater to their specific needs and preferences. Local special circumstances in Lithuania also contribute to the development of the Digestives & Intestinal Remedies market. The country has a high prevalence of digestive disorders, such as irritable bowel syndrome and acid reflux, which drives the demand for related remedies. Additionally, the aging population in Lithuania is increasing, leading to a higher demand for digestive health products among older adults. Furthermore, the government has been promoting preventive healthcare and wellness initiatives, which creates awareness and encourages the use of Digestives & Intestinal Remedies. Underlying macroeconomic factors, such as the increasing disposable income and improving healthcare infrastructure in Lithuania, also play a role in the development of the market. As the economy grows and people have more purchasing power, they are willing to spend on healthcare products, including Digestives & Intestinal Remedies. The improving healthcare infrastructure ensures better access to healthcare services and products, further driving the demand for digestive health remedies. Overall, the Digestives & Intestinal Remedies market in Lithuania is developing due to changing customer preferences, emerging trends, local special circumstances, and underlying macroeconomic factors. The market is expected to continue growing as consumers prioritize their digestive health and seek effective and convenient remedies.

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.